TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29989107

Group type: EXPERIMENTAL
Intervention: 6‐mm implants (experimental)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10‐mm implants with vertical augmentation (control)
Number of subjects: 50
Study: 28963315

Group type: EXPERIMENTAL
Intervention: Reduced prednisolone schedule
Number of subjects: 144

Group type: COMPARATOR
Intervention: Current standard therapy
Number of subjects: 144
Study: 26791167

Group type: EXPERIMENTAL
Intervention: Exercise + Dual-task training (EDT)
Number of subjects: 44
Study: 23545101

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine (2,000 mg/50 cc weekly for 6 weeks, maintenance monthly for 1 year)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1/3 dose Bacillus Calmette‐Guérin (weekly for 6 weeks, maintenance 3 weekly instillations at 3, 6 and 12 months)
Number of subjects: 120
Study: 19553063

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT) plus individual‐based treatment (IBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Individual‐based treatment (IBT) only
Number of subjects: 100
Study: 16423517

Group type: EXPERIMENTAL
Intervention: Nebulization of salbutamol (0.15mg/kg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Puffs of beta 2 agonist (salbutamol 50 microg/kg or terbutaline 125 microg/kg) via spacer
Number of subjects: 79
Study: 15269990

Group type: EXPERIMENTAL
Intervention: PGE1 (0.04 microg.kg(‐1).min(‐1) of Lipo‐PGE1 from the beginning of surgery to the end of study)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no PGE1 given)
Number of subjects: 30
Study: 11403976

Group type: EXPERIMENTAL
Intervention: Lupron-induced hypogonadism
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lupron plus estradiol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lupron plus progesterone replacement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Women with PMS
Number of subjects: 9
Study: 9264427

Group type: EXPERIMENTAL
Intervention: Oral L-arginine (6 g/day for 3 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8353434

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution 0.3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic solution 0.5%
Number of subjects: 0
Study: 3620283

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐11) M
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐10) M
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐9) M
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 31987562

Group type: EXPERIMENTAL
Intervention: Kinesio Taping® for lateral rotation of the femur and tibia (KT-LRFT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Kinesio Taping® for patellar medialization (KT-PM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43
Study: 28771070

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (tele-rehab)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Office-based physical therapy (OBPT)
Number of subjects: 54
Study: 27030575

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 2

Group type: COMPARATOR
Intervention: High-intensity eccentric exercise
Number of subjects: 2
Study: 25090804

Group type: EXPERIMENTAL
Intervention: V-Y capsulorraphy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pants-over-vest capsulorraphy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (SF-36 total)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (Kitaoka score)
Number of subjects: 88
Study: 23321194

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg orally 2 hours before surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 51
Study: 20101071

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18195263

Group type: EXPERIMENTAL
Intervention: [(18)F]fluoro‐l‐dopa uptake in TLE patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphologic assessment using voxel‐based morphometry in TLE patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose metabolism assessment in TLE patients
Number of subjects: 12
Study: 16168153

Group type: EXPERIMENTAL
Intervention: TAU plus CBT
Number of subjects: 90

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 90
Study: 12521974

Group type: EXPERIMENTAL
Intervention: Nurse led secondary prevention clinics
Number of subjects: 1343
Study: 10824634

Group type: EXPERIMENTAL
Intervention: Low-dose pirenzepine (0.5 mg intravenous bolus followed by continuous infusion of 0.15 microg/kg/min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Transdermal scopolamine treatment
Number of subjects: 17
Study: 8863968

Group type: EXPERIMENTAL
Intervention: Prophylaxis with 0.12% chlorhexidine paste
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylaxis using a 13,500 ppm fluoridated pumice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prophylaxis with pumice only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Residual adhesive on enamel surfaces
Number of subjects: 36
Study: 8420815

Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day) in normal subjects
Number of subjects: 15
Study: 3769568

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Bilateral arm venograms
Number of subjects: 3
Study: 30307957

Group type: EXPERIMENTAL
Intervention: Customer self-audit based on the CenteringPregnancy® model of prenatal group care
Number of subjects: 185

Group type: COMPARATOR
Intervention: Individual care (control group)
Number of subjects: 185
Study: 27278385

Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RG; n=50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Walking group (WG; n=50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (CG; n=50)
Number of subjects: 150
Study: 24725239

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 24 weeks
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 865
Study: 22689695

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 20875504

Group type: EXPERIMENTAL
Intervention: Action observation treatment (AOT) in addition to conventional physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional physiotherapy only (Control group)
Number of subjects: 60
Study: 18212199

Group type: EXPERIMENTAL
Intervention: Very high-fat, low-carbohydrate, protein-permitted (VHFLCPP) diet
Number of subjects: 161

Group type: COMPARATOR
Intervention: Fasting protocol
Number of subjects: 161
Study: 15721704

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hansatome mechanical microkeratome
Number of subjects: 51
Study: 12720616

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Turbohaler training
Number of subjects: 30
Study: 10576300

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 8942687

Group type: COMPARATOR
Intervention: Ayre spatula, Cytobrush, or cotton swab used alone
Number of subjects: 85000

Group type: EXPERIMENTAL
Intervention: Extended tip spatula, Ayre spatula combined with Cytobrush or cotton swab, or Cervex brush
Number of subjects: 85000

Group type: COMPARATOR
Intervention: Cytological methods
Number of subjects: 85000

Group type: COMPARATOR
Intervention: Histological methods
Number of subjects: 85000
Study: 1844694

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Component therapies
Number of subjects: 0
Study: 6421143

Group type: EXPERIMENTAL
Intervention: Elemental formula (predigested protein-low fat)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Polymeric formula (intact protein-standard fat)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Solid food standard hospital diet
Number of subjects: 2
Study: 30696336

Group type: EXPERIMENTAL
Intervention: Weight bearing aerobic exercise and resistance exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 55
Study: 29261439

Group type: COMPARATOR
Intervention: Abiraterone plus prednisone (arm A)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone with veliparib (arm B)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Patients with DNA-damage repair defect (DRD)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Patients with normal PTEN
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Patients with normal TP53
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Patients with normal PIK3CA
Number of subjects: 148
Study: 26906713

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg and 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide LAR 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 0
Study: 24777114

Group type: EXPERIMENTAL
Intervention: Barefoot running
Number of subjects: 21

Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 21
Study: 22750189

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 147
Study: 20681235

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CMG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study: 18091407

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 4162
Study: 15598196

Group type: EXPERIMENTAL
Intervention: Methadone plus injectable heroin or methadone plus inhalable heroin prescribed over 12 months (heroin maximum 1000 mg per day, methadone maximum 150 mg per day)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard methadone maintenance treatment
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (previously participated in abstinence-oriented treatment)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Methadone treatment (previously participated in abstinence-oriented treatment)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (no experience in abstinence-oriented treatment)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (no experience in abstinence-oriented treatment)
Number of subjects: 430
Study: 12082591

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study: 11051015

Group type: EXPERIMENTAL
Intervention: Low-dose ESWT (3 x 5000 impulses, no anesthesia)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose ESWT (1 x 5000 impulses, intravenous analgesia)
Number of subjects: 50
Study: 7792414

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 58
Study: 2185681

Group type: EXPERIMENTAL
Intervention: Latex rubber catheters
Number of subjects: 84

Group type: COMPARATOR
Intervention: PVC catheters
Number of subjects: 84
Study: 246947

Group type: EXPERIMENTAL
Intervention: Talampicillin hydrochloride
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 9
Study: 31764387

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 36
Study: 30665390

Group type: EXPERIMENTAL
Intervention: Anaemia testing using HemoCue B‐Haemoglobin analyser
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Knowledge of the term 'anaemia'
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Living in moderately food insecure households
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Early adolescence period (10-14 years)
Number of subjects: 1323
Study: 28614793

Group type: EXPERIMENTAL
Intervention: 600 mg of CBD
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26275928

Group type: EXPERIMENTAL
Intervention: NaF 500ppm F(‐)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NaF 1450ppm F(‐)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AlF3 1360ppmF(‐)+chlorhexidine 0.05% (Lacalut aktiv, LA1360)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0ppm F(‐) (negative control)
Number of subjects: 16
Study: 23365066

Group type: EXPERIMENTAL
Intervention: eTNS 120 Hz
Number of subjects: 50

Group type: COMPARATOR
Intervention: eTNS 2 Hz
Number of subjects: 50
Study: 20452785

Group type: EXPERIMENTAL
Intervention: Hematoma evacuation
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: External ventricular drainage (EVD)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Neurosurgery (general)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Control (no neurosurgery)
Number of subjects: 821
Study: 19517101

Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 1 mg/kg/day artesunate
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 2 mg/kg/day artesunate
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 4 mg/kg/day artesunate
Number of subjects: 115

Group type: COMPARATOR
Intervention: CPG-DDS alone (2/2.5 mg/kg/day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CPG-DDS plus artesunate
Number of subjects: 115
Study: 17355738

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment (3 mg/day to 9 mg/day over time)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (maintained on current antipsychotic medication)
Number of subjects: 20
Study: 15209317

Group type: EXPERIMENTAL
Intervention: Moderate arousal intensity in steep-gradient arousal conditions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rate of arousal increase
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increased movement and exertion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Participants' affect
Number of subjects: 80
Study: 11682414

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation with oxygen 100% for 2 minutes after 1 minute of oxygen 100% (Group H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoxygenation with oxygen 100% for 3 minutes (Group P)
Number of subjects: 30
Study: 9762777

Group type: EXPERIMENTAL
Intervention: Asthmatic patients with PEF variation >15%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Asthmatic patients with PEF variation < or =15%
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 7523735

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using prostate specific antigen and digital rectal examination
Number of subjects: 74000
Study: 2458686

Group type: EXPERIMENTAL
Intervention: neurolept anesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: isoflurane anesthesia without narcotics
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CSF substance P concentrations before the start of PCA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: individual changes in substance P concentrations during PCA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CSF (Met)enkephalin‐Arg6‐Phe7 concentrations
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: interindividual variability in substance P and (Met)enkephalin‐Arg6‐Phe7 concentrations
Number of subjects: 14
Study: 31676670

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Durvalumab (arm B)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tremelimumab (arm C)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm D)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tumor-based IFNγ gene signature (arm E)
Number of subjects: 113
Study: 29050009

Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravitreal Triamcinolone
Number of subjects: 208
Study: 28098954

Group type: EXPERIMENTAL
Intervention: Play therapy
Number of subjects: 0
Study: 26591681

Group type: EXPERIMENTAL
Intervention: Massage treatment 1 and 2
Number of subjects: 180

Group type: COMPARATOR
Intervention: Basic treatment 1 and 2
Number of subjects: 180
Study: 24134956

Group type: EXPERIMENTAL
Intervention: Personalized self-management support using the SeMaS questionnaire
Number of subjects: 15

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 15
Study: 20349353

Group type: EXPERIMENTAL
Intervention: Patients receiving cancer treatment
Number of subjects: 285

Group type: COMPARATOR
Intervention: Patients awaiting new treatment
Number of subjects: 285

Group type: COMPARATOR
Intervention: Patients on surveillance or whose treatment had been stopped
Number of subjects: 285
Study: 19004162

Group type: COMPARATOR
Intervention: Weight-loss supplement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Telephone coaching
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both supplement and coaching
Number of subjects: 120
Study: 16990155

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and diet counselling)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 151
Study: 13130145

Group type: EXPERIMENTAL
Intervention: NSAID therapy
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study: 12212248

Group type: EXPERIMENTAL
Intervention: Low volume ventilation (tidal volume 6-8 ml.kg-1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal volume ventilation (tidal volume 12-14 ml.kg-1)
Number of subjects: 35
Study: 8941026

Group type: EXPERIMENTAL
Intervention: Didanosine (300 mg) administered orally and intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Didanosine (300 mg) administered orally 4 hours before hemodialysis
Number of subjects: 16
Study: 14621771

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10 mg/kg per day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 49
Study: 3932470

Group type: EXPERIMENTAL
Intervention: Dobutamine infusions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusions (control)
Number of subjects: 24
Study: 31422740

Group type: EXPERIMENTAL
Intervention: Self-Controlled Knowledge of Results (SC KR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Yoked Control Group
Number of subjects: 24
Study: 29859570

Group type: EXPERIMENTAL
Intervention: Differential Interaural Intensity Difference (DIID) training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dichotic Offset Training (DOT)
Number of subjects: 12
Study: 27062041

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (250 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypoxia without vitamin E supplementation
Number of subjects: 9
Study: 24577880

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (PDT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 47
Study: 22812731

Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure treatment for patients with obstructive sleep-disordered breathing (apnea hypopnea index ≥20)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuous positive airways pressure treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Assessment of vascular functions and markers (blood pressure, heart rate variability, endothelial function, specific humoral factors)
Number of subjects: 200
Study: 19266407

Group type: EXPERIMENTAL
Intervention: Bonding social capital (treatment and emotional buddy)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Bridging social capital (community health worker and support group)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Bonding and bridging social capital
Number of subjects: 268
Study: 17585003

Group type: EXPERIMENTAL
Intervention: NAAGA eye-drops
Number of subjects: 23

Group type: COMPARATOR
Intervention: LEVO eye-drops
Number of subjects: 23
Study: 16114155

Group type: EXPERIMENTAL
Intervention: Cyclogest (n=35)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Crinone gel (n=36)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Utrogestan (n=55)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HCG (n=35)
Number of subjects: 161
Study: 11799502

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (group R2, n = 19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (group R1, n = 19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with 2 microg/mL fentanyl (group RF, n = 20)
Number of subjects: 58
Study: 10512907

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 17
Study: 7992988

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 65000

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 65000

Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 65000

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 65000

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 65000
Study: 1941733

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms twice daily for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25